Moreover, DLBCL patients with lower circ-APC levels were more likely to exhibit an advanced Ann Arbor stage, shorter OS, resist chemotherapy and display a low International Prognostic Index (Hu et al., 2019). This evidence concerns the gene APC and diffuse large B-cell lymphoma.